Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors

Activation of immune checkpoint pathways and limited T- cell infiltration result in immunological escape of tumors. Although immune checkpoint inhibitors are currently approved for several types of cancers, the response rate is often limited by the lack of tumor specific T-cells within the malignant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Feola, S., Capasso, C., Fusciello, M., Martins, B., Tähtinen, S., Medeot, M., Carpi, S., Frascaro, F., Ylosmäki, E., Peltonen, K., Pastore, L., Cerullo, V.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136871/
https://ncbi.nlm.nih.gov/pubmed/30221051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1457596
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados